Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

FuelCell Energy FCEL is trading below its 50-day and 200-day simple moving average (SMA), signaling a bearish trend. FCEL ...

SonicWall, which learned about the zero-day from Microsoft, initially said it was aware of “possible active exploitation”, ...

CLX looks poised for growth through recent recovery, improved distribution channels and focus on innovation and expansion ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

The company also plans to initiate the Phase 2 OPAL trial in mid-2025 to study apitegromab in SMA patients under two years of age. Apitegromab is a fully human monoclonal antibody that inhibits ...

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

Nearly 3,700 SonicWall SMA 1000 series VPNs are exposed to the internet after disclosure of a recently discovered critical ...

Columnist Helen Baldwin gains a different perspective following a crushing diagnosis, but glasses weren't what helped her to see clearly.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...